Clinical Efficacy of Lifei Xiaoji Wan in Treatment of Advanced NSCLC
Status: Recruiting
Location: See location...
Intervention Type: Other, Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This study is to evaluate the clinical efficacy of Lifei Xiaoji Wan for advanced non-small cell lung cancer (NSCLC), establish the treatment scheme, and obtain high-quality clinical evidence.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Clinical diagnosis of NSCLC.
• The tumor stage (TNM) stage is from III to IV.
• 18-80 years old.
• The expected survival period is\> 3 months.
Locations
Other Locations
China
the First Affiliated Hospital of Henan University of Chinese Medicine
RECRUITING
Zhengzhou
Contact Information
Primary
Yuanyuan Wang, MD
40685685@qq.com
0371-66248624
Time Frame
Start Date: 2022-06-01
Estimated Completion Date: 2024-12-31
Participants
Target number of participants: 100
Treatments
Experimental: trial group
The patients in the trial group received routine Western medicine treatments, and oral Lifei Xiaoji Wan (10 pills/time, 3 times/day).
No_intervention: control group
The patients in the control group received routine Western medicine treatments.
Related Therapeutic Areas
Sponsors
Leads: Henan University of Traditional Chinese Medicine